Vericel (NASDAQ:VCEL) Insider Sean Flynn Sells 15,000 Shares of Stock

Vericel Corporation (NASDAQ:VCEL) insider Sean Flynn sold 15,000 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $51.92, for a total transaction of $778,800.00. Following the completion of the transaction, the insider owned 1,990 shares in the company, valued at $103,320.80. This trade represents a 88.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Vericel Price Performance

Shares of VCEL traded up $2.84 on Friday, reaching $54.62. The company’s stock had a trading volume of 1,612,192 shares, compared to its average volume of 598,922. The stock has a market capitalization of $2.80 billion, a P/E ratio of 116.22 and a beta of 1.08. The stock’s 50 day simple moving average is $40.74 and its two-hundred day simple moving average is $38.80. Vericel Corporation has a 12-month low of $28.95 and a 12-month high of $55.60.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.21. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The business had revenue of $85.37 million during the quarter, compared to analysts’ expectations of $77.95 million. During the same period in the prior year, the company earned $0.10 earnings per share. The firm’s revenue was up 26.5% on a year-over-year basis. Analysts expect that Vericel Corporation will post 0.54 earnings per share for the current year.

Key Stories Impacting Vericel

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Third-quarter revenue rose 26% year over year to $85.4 million, while earnings were $0.27 per share—well above analyst estimates. Net income increased 179% to $14.2 million; the company also cited record MACI sales. Vericel Q3 2026 results and guidance
• Positive Sentiment: Vericel raised its 2026 revenue guidance to $344–$346 million, above the approximately $336 million consensus, and increased its adjusted EBITDA margin guidance to 28%. Vericel Q3 2026 results and guidance
• Positive Sentiment: HC Wainwright raised its price target from $72 to $75 and reaffirmed a Buy rating, signaling continued analyst confidence after the results. HC Wainwright raises Vericel price target
• Negative Sentiment: A separate analysis described VCEL as potentially overvalued relative to its earnings support, a risk if future growth does not justify investor expectations. Analysis of Vericel’s valuation

Hedge Funds Weigh In On Vericel

Large investors have recently added to or reduced their stakes in the company. Allworth Financial LP boosted its position in shares of Vericel by 53.0% in the third quarter. Allworth Financial LP now owns 2,052 shares of the biotechnology company’s stock worth $91,000 after purchasing an additional 711 shares during the period. Gagnon Securities LLC increased its stake in shares of Vericel by 7.3% in the third quarter. Gagnon Securities LLC now owns 7,839 shares of the biotechnology company’s stock worth $315,000 after purchasing an additional 536 shares in the last quarter. Maryland State Retirement & Pension System raised its position in shares of Vericel by 53.3% during the 3rd quarter. Maryland State Retirement & Pension System now owns 11,395 shares of the biotechnology company’s stock valued at $457,000 after purchasing an additional 3,963 shares during the period. Illinois Municipal Retirement Fund bought a new stake in shares of Vericel during the 3rd quarter valued at $1,071,000. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Vericel by 0.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 157,081 shares of the biotechnology company’s stock valued at $6,195,000 after purchasing an additional 435 shares during the period.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Truist Financial set a $65.00 price objective on Vericel in a research note on Friday. TD Cowen lifted their target price on Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Weiss Ratings restated a “hold (c)” rating on shares of Vericel in a research report on Thursday, October 29th. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Canaccord Genuity Group set a $60.00 price objective on Vericel in a research note on Thursday, July 30th. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $60.80.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.